Washington: RTS,S malaria candidate vaccine can help protect African infants against malaria, results from a pivotal, large-scale Phase III trial, have suggested.
When compared to immunization with a control vaccine, infants (aged 6-12 weeks at first vaccination) vaccinated with RTS,S had one-third fewer episodes of both clinical and severe malaria and had similar reactions to the injection. In this trial, RTS,S demonstrated an acceptable safety and tolerability profile.
Eleven African research centres in seven African countries are conducting this trial, together with GlaxoSmithKline (GSK) and the PATH Malaria Vaccine Initiative (MVI), with grant funding from the Bill and Melinda Gates Foundation to MVI.
“This study indicates that RTS,S can help to protect young babies against malaria. Importantly, we observed that it provided this protection in addition to the widespread use of bed nets by the trial participants,” said Dr. Salim Abdulla, a principal investigator for the trial from the Ifakara Health Institute, Tanzania.
When administered along with standard childhood vaccines, the efficacy of RTS,S in infants aged 6 to 12 weeks (at first vaccination) against clinical and severe malaria was 31 percent and 37 percent respectively, over 12 months of follow-up after the third vaccine dose.
Insecticide-treated bed nets were used by 86 percent of the trial participants, which demonstrated that RTS,S provided protection beyond existing malaria control interventions.
The efficacy observed with RTS,S last year in children aged 5-17 months of age against clinical and severe malaria was 56 percent and 47 percent, respectively. Follow-up in this Phase III trial will continue and is expected to provide more data for analyses to better understand the different findings between the age categories.
The vaccine is being developed in partnership by GSK and MVI, together with prominent African research centres.
The study has been published online in the New England Journal of Medicine.